Last reviewed · How we verify
TMC114
TMC114 is a protease inhibitor used to treat HIV-1 infection.
TMC114 is a protease inhibitor used to treat HIV-1 infection. Used for Treatment of HIV-1 infection in treatment-experienced adult patients, Treatment of HIV-1 infection in treatment-naive adult patients.
At a glance
| Generic name | TMC114 |
|---|---|
| Also known as | Darunavir |
| Sponsor | Tibotec Pharmaceuticals, Ireland |
| Drug class | protease inhibitor |
| Target | HIV-1 protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
TMC114 works by inhibiting the protease enzyme, which is essential for the replication of the HIV-1 virus. This inhibition prevents the virus from producing new viral particles, thereby reducing the viral load in the body.
Approved indications
- Treatment of HIV-1 infection in treatment-experienced adult patients
- Treatment of HIV-1 infection in treatment-naive adult patients
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Dizziness
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV (PHASE1, PHASE2)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- The Late Presenter Treatment Optimisation Study (PHASE3)
- Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMC114 CI brief — competitive landscape report
- TMC114 updates RSS · CI watch RSS
- Tibotec Pharmaceuticals, Ireland portfolio CI